


# Advancing the state of the art in neutralizing stronger COVID-19 variants

November 22 2022




The development process of the hACE2 receptor-mimicking hybrid neutralizer. The peptide-nucleic acid hybrid neutralizer developed through the research team's proprietary expertise in in vitro evolution technology (HOLD) shows remarkable neutralizing efficacy against COVID-19 virus variants. Credit: POSTECH

The emergence of unpredictable variants and their stronger infectivity make the COVID-19 pandemic never-ending—over 300 omicron variants have been reported so far. Will there ever be a universal cure for COVID-19 that neutralizes the various mutated strains of the virus?

A research team led by Professor Seung Soo Oh (Department of Materials Science and Engineering) has developed a tailored COVID-19 neutralizer that can adapt to all kinds of mutations in the [virus](#) in treating the viral infection. This neutralizing agent is designed to exhibit a stronger effect by utilizing the same mechanism that viruses use to become stronger in infection through [evolutionary processes](#).

The reason behind the increasing infectivity of the coronavirus with repeated mutations is that the virus can change its structure and thus increase the strength of its interaction with the angiotensin-converting enzyme (hACE2) receptor, a cell surface protein. Conventional treatments and neutralizing technologies fail to immediately respond to these newly emerging variants.

The research team found an innovative way to suppress cell infection by mimicking the principle of hotspot interaction between the virus and the hACE2 receptor. The newly developed hybrid neutralizer, consisting of a protein fragment and [nucleic acids](#), can strongly bind to the coronavirus, which causes the virus not to interact with the hACE2 receptor, eventually inhibiting its penetration into the cells.



**“Stronger neutralization as SARS-CoV-2 mutates”**

Performance evaluation of major coronavirus variants reported to date (top) and the effect of hybrid neutralizers on each variant (bottom). Credit: POSTECH

This neutralizer draws attention as it was based on the research team's proprietary expertise in in vitro evolution technology called Hotspot-Oriented Ligand Display (HOLD). The HOLD is an evolutionary technology that automatically selects the most suitable material out of the 10 trillion candidate materials for binding to the virus, and the principle behind HOLD resembles the theory of natural selection.

The study reported that this hybrid agent has an excellent neutralizing effect not only against the alpha, beta, gamma, and delta variants but also the omicron [variant](#), which is known to be the most contagious. The neutralizing performance of this agent against the omicron variant (equilibrium dissociation constant) was found to be 1.209 nanomoles, which is about 5 times higher than the observed neutralizing performance against the earlier strain of coronavirus (5.702 nM).

Professor Seung Soo Oh explained, "It is significant that we have developed the world's first self-evolving neutralizer-developing platform that shows increasingly better performance with the occurrence of viral mutations." He added, "We plan to develop it into a core technology that can respond to the next-generation pandemic viruses, such as influenza and Hantavirus."

This study was published in *Science Advances*.

**More information:** Minjong Lee et al, De novo selected hACE2 mimics that integrate hotspot peptides with aptameric scaffolds for binding tolerance of SARS-CoV-2 variants, *Science Advances* (2022). [DOI: 10.1126/sciadv.abq6207](https://doi.org/10.1126/sciadv.abq6207)

Provided by Pohang University of Science & Technology (POSTECH)

Citation: Advancing the state of the art in neutralizing stronger COVID-19 variants (2022, November 22) retrieved 3 May 2024 from <https://medicalxpress.com/news/2022-11-advancing-state-art-neutralizing-stronger.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.